NVCR

Novocure

• Seeking Alpha·5h ago

  Big movers after the closing bell: COST, NVCR, PNW

• Simply Wall St·3d ago

  Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation?

• NASDAQ·07/01 17:00

  NovoCure's Cancer Treatment Device Option Pax Gets European Approval

• PUBT·07/01 11:00

  Novocure to report Q2 results, host conference call and webcast

• TipRanks·06/30 13:05

  Wedbush Remains a Hold on NovoCure (NVCR)

• TipRanks·06/30 11:28

  Novocure’s Optune Pax Secures CE Mark for Pancreatic Cancer

• Benzinga·06/30 11:11

  Novocure Says Optune Pax Receives CE Mark For Treatment Of Adult Patients With Locally Advanced Pancreatic Cancer Of Exocrine Origin, Concomitant With Gem/Nab-Pac

• TipRanks·06/30 11:11

  Novocure announces Optune Pax received CE Mark

• PUBT·06/30 11:00

  Novocure wins CE mark for Optune Pax in locally advanced pancreatic cancer treatment

• Reuters·06/30 11:00

  NOVOCURE’S OPTUNE PAX® RECEIVES CE MARK FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER

• Simply Wall St·06/27 12:17

  NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start

• Simply Wall St·06/26 06:18

  NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results

• The Motley Fool·06/24 19:05

  HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

• TipRanks·06/23 15:06

  Wedbush Initiates a Hold Rating on NovoCure (NVCR)

• The Motley Fool·06/22 14:59

  NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?